首页> 外文OA文献 >PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)

【2h】

PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)

机译：PD3-2-6：厄洛替尼用于晚期非小细胞肺癌（NSCLC）的开放标签TRUST（TaRceva lUng Cancer Survival Treatment）研究的东亚/东南亚（E / SE）亚洲亚组的中期安全性结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Park Keunchil; Lee Jong-Seok; Wu Yi-Long; Zhang Li; Cheng Ashley; Siu-Kie-Au Joseph; Voravud Narin; Muthalib Abdul; Wahid Mohd Ibrahim A.; Yang Chih-Hsin;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. 6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study [J] . E.Smit, M.Reck, M.Krzakowski, European Journal of Cancer Supplements . 2007 ,第4期

机译：晚期非小细胞肺癌（NSCLC）患者的6510 ORAL厄洛替尼：开放标签TRUST研究的欧洲亚人群的中期结果
2. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. [J] . Reck M, van Zandwijk N, Gridelli C, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2010 ,第10期

机译：厄洛替尼治疗晚期非小细胞肺癌：全球第四期特罗凯肺癌生存治疗研究的疗效和安全性研究。
3. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study [J] . CiuleanuT., StelmakhL., CicenasS., The lancet oncology . 2012 ,第3期

机译：厄洛替尼与化学疗法在二线治疗预后不良的晚期非小细胞肺癌（TITAN）患者中的疗效和安全性：一项随机，多中心，开放标签的3期研究
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Use of Palliative Radiotherapy Among Metastatic Non-small-cell Lung Cancer (NSCLC) Patients in Puerto Rico [D] . ?Quinones Avila, Valerie 2020

机译：在波多黎各的转移性非小细胞肺癌（NSCLC）患者中使用姑息放射治疗
6. Pemetrexed-Erlotinib Pemetrexed Alone or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial [O] . Dae Ho Lee, Jung Shin Lee, Jie Wang, 2015

机译：培美曲塞-厄洛替尼单独培美曲塞或单独埃罗替尼作为患有局部晚期或转移性非鳞状非小细胞肺癌的东亚和非东亚非吸烟者的二线治疗：II期试验的探索性亚组分析
7. B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) [O] . Ardizzoni Andrea, Razis Evangelia, Lichinitser Mikhail, 2007

机译：B3-06：TRUST的中期安全性结果是埃洛替尼在晚期非小细胞肺癌（NSCLC）患者中进行的全球开放标签研究

PD3-2-6: Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC)

著录项

相似文献

相关主题

期刊订阅